Abcam, ab240083, Anti-CD79b antibody [EPR6861] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal CD79b antibody. Carrier free. Suitable for IHC-P, Flow Cyt, WB, ICC/IF and reacts with Rat, Chicken, Pigeon, Serinus canarius, Human, Mouse, Cat, Dog, Horse, Pig, Llama, Cow, Goat, Sheep samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR6861,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human, Cat, Dog, Horse, Pig, Llama, Cow, Goat, Sheep, Chicken, Pigeon, Serinus canarius,
Applications:Flow Cyt, ICC/IF, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab240083 is the carrier-free version of
ab134147
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD79b also known as Ig-beta is a protein that plays a mechanical role as part of the B-cell antigen receptor complex. This protein with a mass of approximately 40 kDa is mainly expressed on the surface of B lymphocytes. It is an important component of the heterodimeric complex composed of CD79a (Ig-alpha) and CD79b which associates with membrane-bound immunoglobulins to form the B-cell receptor (BCR). CD79b is essential for transducing activation signals following antigen binding to the BCR.
Biological function summary
The primary role of CD79b within the immune system is to support signal transduction. Upon binding of an antigen to BCR on B cells CD79b as part of the BCR complex initiates signaling cascades which lead to B-cell activation proliferation and differentiation. These processes are critical for humoral immunity ensuring adequate antibody production. CD79b is often found in association with CD19 another important B-cell surface protein and together they aid in amplifying the signals required for B-cell response.
Pathways
CD79b is deeply involved in the B-cell receptor signaling pathway and the broader adaptive immune response. Once the BCR is engaged by an antigen CD79b helps activate intracellular signaling pathways that involve kinases such as SYK and BLNK which help propagate and amplify the immune response. These pathways also interact with other receptor components like CD22 and CD19 creating a network of interactions ensuring effective pathogen recognition and response.
CD79b carries significant relevance in the context of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and some types of lymphoma. Dysregulation or mutations in CD79b can affect BCR signaling leading to unchecked B-cell proliferation characteristic of these diseases. Additionally CD79b's interaction with proteins such as SYK in the signaling pathways makes it a potential therapeutic target in treating B-cell related cancers. Researchers are actively investigating anti-CD79b therapies to disrupt abnormal signaling in B-cell malignancies.